>One hurdle that will need to be overcome is that NF-Y also regulates important processes in healthy cells, such as metabolism and the cell cycle, the series of steps that cells go through as they grow and divide. However, Vakoc and team hypothesize that because RMS cells are "highly sensitive" to changes in PAX3-FOXO1 expression, there could be a "window of opportunity" in which a drug inhibits NF-Y long enough for RMS cells to differentiate but not so long that healthy tissues get damaged.

Author buried the most important "but.." in the last paragraph. Lets keep "sciencing", but this is just a catchy headline.